Rare liver tumors like combined HCC/CCA, fibrolamellar HCC, and haemangioendothelioma pose significant diagnostic and therapeutic challenges. In this episode, we explore the latest insights, controversies, and clinical approaches outlined in the new EASL position paper. Join us to uncover how these advancements can address key hurdles in managing these rare malignancies. Read the position paper: Rare primary liver cancers: An EASL position paper Moderator: Thomas Berg Faculty: Ruben de Kleine and Henning Wege Related episodes S6E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond S5E13: Basics in decision-making for liver cancer treatment S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.